Challenge and vision
The critical point has been identified: the transfer of dirt and residue from outdoors into indoor spaces.
Product development
HYGEN KLINX is an evolving project. Each stage turns a clear vision into a concrete, verifiable solution designed for everyday use.
Project status
The roadmap progresses through functional definition, design, prototyping, testing and industrialisation. Final performance will only be communicated after appropriate validation.
The critical point has been identified: the transfer of dirt and residue from outdoors into indoor spaces.
We are translating PET, HOME, Standalone and Building solutions into distinct technical requirements.
Prototypes and test protocols will verify user experience, safety and performance.
Roadmap
Analysis of entrance settings, real-world behaviour and the requirements of different users.
Definition of flows, dimensions, components and interactions for PET and HOME solutions.
Building and iterating functional prototypes to assess components, interactions and usage sequences.
Verification of ergonomics, reliability, safety and performance through dedicated protocols.
Production optimisation, supply chain, compliance and market readiness.
Behind the project
The project combines user experience, architectural integration and a system logic designed to evolve over time.

The system is designed to become a natural part of the entrance.

Confidential details remain protected throughout technical development.

PET, HOME, Standalone and Building share one coherent vision.
Method
HYGEN KLINX development brings together user experience, safety and measurable performance. Prototypes and dedicated tests will guide technical decisions, supported by partners with expertise in engineering, validation and industrialisation.

Take part in development
The next standard is built with the right expertise.
If you represent an industrial partner or an organisation interested in Building solutions, tell us which role you would like to explore. Investment opportunities follow the dedicated Investor Relations path.